查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1668103

骨髓增生異常綜合症治療市場 - 全球行業規模、佔有率、趨勢、機會和預測，按治療類型、按最終用戶、按地區和競爭細分，2020-2030 年預測

Myelodysplastic Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球骨髓增生異常症候群 (MDS) 治療市場價值為 29.5 億美元，預計到 2030 年將達到 42 億美元，預測期內複合年成長率為 6.02%。骨髓增生異常綜合症 (MDS) 是一組以骨髓血球生成功能障礙為特徵的血液疾病。它會影響紅血球、白血球和血小板的生成，導致各種症狀和併發症。多年來，MDS 的診斷和治療取得了重大進展，導致全球 MDS 治療市場不斷成長。 MDS 主要影響老年人，但它可能發生在任何年齡。它通常被認為是白血病前期病症，因為它可能發展為急性骨髓性白血病 (AML)。 MDS 的具體病因尚不清楚，但據信與基因突變、接觸某些化學物質和放射療法有關。

市場概況
預測期 2026-2030
2024 年市場規模 29.5 億美元
2030 年市場規模 42 億美元
2025-2030 年複合年成長率 6.02%
成長最快的領域 醫院和診所
最大的市場 北美洲

受多種因素推動，全球骨髓增生異常綜合症 (MDS) 治療市場正在穩步成長。隨著全球人口老化，MDS 的發生率預計會上升。這種人口結構的變化導致對 MDS 治療的需求增加。醫療保健提供者和患者對 MDS 的認知不斷提高，從而實現了更早的診斷和干涉，進一步促進了市場的成長。由於醫療保健基礎設施的改善和先進療法的普及，發展中經濟體正在成為 MDS 治療市場中越來越重要的參與者。製藥公司和政府機構對 MDS 研究和開發持續的投資預計將帶來創新的治療方案並擴大市場。

近年來，全球骨髓增生異常綜合症治療市場取得了顯著進步，為患有這種棘手疾病的患者帶來了新的希望。標靶治療、個人化醫療、改進的支持性護理以及正在進行的臨床試驗正在改變 MDS 治療的模式。隨著人口老化加劇和人們認知的不斷提高，MDS 治療市場將持續擴大，最終為與疾病作鬥爭的患者帶來更好的治療效果並提高其生活品質。

主要市場促進因素

呼吸系統疾病盛行率上升推動全球骨髓增生異常綜合症 (MDS) 治療市場發展

主要市場挑戰

定價壓力

主要市場趨勢

技術進步

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球骨髓增生異常綜合症 (MDS) 治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療類型（幹細胞移植、免疫治療、化療、免疫調節藥物、抗貧血藥物、其他）
    • 按最終使用者（醫院和診所、門診護理中心、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第 6 章：北美骨髓增生異常症候群 (MDS) 治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第 7 章：歐洲骨髓增生異常症候群 (MDS) 治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區骨髓增生異常症候群 (MDS) 治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲骨髓增生異常症候群 (MDS) 治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲骨髓增生異常綜合症 (MDS) 治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如果有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • AbbVie Inc.
  • Accord Healthcare Limited
  • Bristol-Myers Squibb Company
  • Jazz Pharmaceuticals Inc.
  • Novartis AG
  • Lupin Limited
  • Otsuka America Pharmaceutical Inc.
  • Takeda Pharmaceutical Company Limited
  • Astex Therapeutics Limited
  • Pfizer Inc.

第 15 章：策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 19092

Global Myelodysplastic Syndrome (MDS) Treatment Market was valued at USD 2.95 Billion in 2024 and is expected to reach USD 4.20 Billion by 2030 with a CAGR of 6.02% during the forecast period. Myelodysplastic Syndrome (MDS) is a group of blood disorders characterized by dysfunctional blood cell production in the bone marrow. It affects the production of red blood cells, white blood cells, and platelets, leading to a variety of symptoms and complications. Over the years, significant progress has been made in the diagnosis and treatment of MDS, leading to a growing global market for MDS treatment. MDS primarily affects older adults, but it can occur at any age. It is often considered a pre-leukemic condition because it can progress to acute myeloid leukemia (AML). The exact cause of MDS is still unknown, but it is believed to be linked to genetic mutations, exposure to certain chemicals, and radiation therapy.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.95 Billion
Market Size 2030USD 4.20 Billion
CAGR 2025-20306.02%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

The Global Myelodysplastic Syndrome (MDS) Treatment Market is witnessing steady growth, driven by several factors. As the global population continues to age, the incidence of MDS is expected to rise. This demographic shift contributes to an increased demand for MDS treatments. Growing awareness among healthcare providers and patients about MDS has led to earlier diagnosis and intervention, further boosting the market's growth. Developing economies are becoming more significant players in the MDS treatment market due to improvements in healthcare infrastructure and access to advanced therapies. Continued investments in MDS research and development by pharmaceutical companies and government agencies are expected to yield innovative treatment options and expand the market.

The global Myelodysplastic Syndrome treatment market has witnessed remarkable advancements in recent years, offering new hope to patients diagnosed with this challenging condition. Targeted therapies, personalized medicine, improved supportive care, and ongoing clinical trials are transforming the landscape of MDS treatment. With a growing aging population and increasing awareness, the market for MDS treatments is poised for continued expansion, ultimately leading to better outcomes and improved quality of life for patients battling this disease.

Key Market Drivers

Rising Prevalence of Respiratory Diseases is Driving the Global Myelodysplastic Syndrome (MDS) Treatment Market

Respiratory diseases have become a significant global health concern, affecting millions of individuals worldwide. These ailments, which include conditions like asthma, chronic obstructive pulmonary disease (COPD), and bronchitis, can severely impact a person's quality of life and, in some cases, be life-threatening. The rising prevalence of respiratory diseases has led to increased demand for effective treatment options, and one such solution that has gained prominence in recent years is Myelodysplastic Syndrome (MDS) Treatment. Myelodysplastic Syndrome (MDS) Treatment are a form of medication delivery that involves inhaling a nebulized solution through a specialized device. This method is particularly effective for delivering medication directly to the respiratory system, making it a vital component in managing and treating respiratory diseases. The global Myelodysplastic Syndrome (MDS) Treatment market has witnessed significant growth in response to the increasing burden of respiratory diseases. In February 2024, Fortis Healthcare in Mumbai achieved a significant milestone, completing 100 bone marrow transplants, a key treatment for myelodysplastic syndrome, leukemia, and other blood disorders. This accomplishment, along with similar advancements and initiatives, is anticipated to drive growth in the market.

Key Market Challenges

Pricing Pressures

Pricing pressures are a significant challenge in the Myelodysplastic Syndrome (MDS) treatment market as healthcare systems across the globe implement increasingly stringent cost-containment measures. Governments, insurance companies, and payers are placing greater emphasis on cost-effectiveness and value-based healthcare, leading to heightened scrutiny of treatment costs and the value they offer. Pharmaceutical companies are under considerable pressure to demonstrate the clinical and economic value of their products in order to secure reimbursement and negotiate favorable pricing terms. In addition, these companies are tasked with finding ways to lower the overall cost of treatment for patients, including offering more affordable treatment options, exploring alternative delivery methods, or reducing the complexity and duration of therapy. The growing demand for cost-effective solutions is driving the need for innovations that deliver both clinical efficacy and economic viability, compelling drug manufacturers to focus on value-based pricing models that align with payer expectations.

Key Market Trends

Technological Advancements

Technological advancements have consistently played a pivotal role in transforming the landscape of healthcare. One such domain where this transformation is prominently visible is in the treatment of Myelodysplastic Syndrome (MDS), a group of bone marrow disorders that hinder the production of healthy blood cells. The Global Myelodysplastic Syndrome (MDS) Treatment Market is experiencing a significant boost, thanks to the remarkable strides made in technology and research. In March 2020, Gilead Sciences, Inc. and Forty-Seven, Inc. have finalized a deal in which Gilead will purchase Forty-Seven at a price of $95.50 per share in cash. Magrolimab is the primary experimental product being developed by Forty-Seven.

One of the most significant breakthroughs in MDS treatment has been the ability to conduct comprehensive genetic profiling of patients. Advanced genomic sequencing technologies enable doctors to identify specific genetic mutations that drive the development of MDS. This information is crucial in tailoring personalized treatment plans and predicting disease progression accurately. With a better understanding of the genetic basis of MDS, pharmaceutical companies are developing targeted therapies that specifically address the underlying genetic abnormalities. These therapies are more effective and have fewer side effects compared to traditional chemotherapy.

Key Market Players

  • AbbVie Inc.
  • Accord Healthcare Limited
  • Bristol-Myers Squibb Company
  • Jazz Pharmaceuticals Inc.
  • Novartis AG
  • Lupin Limited
  • Otsuka America Pharmaceutical Inc.
  • Takeda Pharmaceutical Company Limited
  • Astex Therapeutics Limited
  • Pfizer Inc.

Report Scope:

In this report, the Global Myelodysplastic Syndrome (MDS) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Myelodysplastic Syndrome (MDS) Treatment Market, By Treatment Type:

  • Stem Cell Transplant
  • Immune Treatments
  • Chemotherapy
  • Immunomodulatory Drugs
  • Anti-Anaemics
  • Others

Myelodysplastic Syndrome (MDS) Treatment Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Myelodysplastic Syndrome (MDS) Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Myelodysplastic Syndrome (MDS) Treatment Market.

Available Customizations:

Global Myelodysplastic Syndrome (MDS) Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Stem Cell Transplant, Immune Treatments, Chemotherapy, Immunomodulatory Drugs, Anti-anemics, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By End User

7. Europe Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By End User
    • 7.3.2. United Kingdom Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By End User
    • 7.3.3. Italy Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By End User
    • 7.3.4. France Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By End User

8. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By End User

9. South America Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By End User

10. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By End User
    • 10.3.3. UAE Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. AbbVie Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Accord Healthcare Limited
  • 14.3. Bristol-Myers Squibb Company
  • 14.4. Jazz Pharmaceuticals Inc.
  • 14.5. Novartis AG
  • 14.6. Lupin Limited
  • 14.7. Otsuka America Pharmaceutical Inc.
  • 14.8. Takeda Pharmaceutical Company Limited
  • 14.9. Astex Therapeutics Limited
  • 14.10. Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer